Rahandusministeerium
Sotsiaalministeerium Meie: 09.11.2020
nr 7-5.13/20-02385-2
Päringu edastamine
Edastan Riigikantseleisse saabunud Euroopa vähihaigete ühenduse ECPC töötaja päringu.
Lugupidamisega
(allkirjastatud digitaalselt)
Heili Tõnisson
Valitsuse nõunik
Stenbocki maja / Rahukohtu 3 / 15161 Tallinn / Estonia / registrikood 700004809
+372 693 5555 /
[email protected] / www.riigikantselei.ee
From: Grazia Scocca <
[email protected]>
Sent: Wednesday, November 4, 2020 1:49 PM
To: Riigikantselei <
[email protected]>
Subject: Request for information - Access to financial instruments Cancer Survivors
Dear Madam, Sir,
I hope my messages finds you well and safe in this difficult time.
My name is Grazia Scocca, I am a legal researcher for the European Cancer Patient Coalition (ECPC), based
in Brussels.
I am addressing you this email, because I am working on a research study on the access to financial services
for cancer survivors. The research is conducted under the supervision of Dr. Franēoise Meunier,
oncologist, member of the Scientific Committee of the ECPC and Vice President of the Federation of the
European Academies of Medicine (FEAM).
The aim of the research project is to assess the level of accessibility for cancer survivors to financial
services, once their treatments end. The research takes into consideration the promulgation of legal
provisions in France, Belgium and Luxembourg on the right to be forgotten for cancer survivors.
The above-mentioned initiatives introduced for cancer survivors the Right to not declare their cancer (10
years after the end of the active treatment and 5 years for cancers under 18 or 21) when they apply for
loans, mortgages, insurances or other financial services.
Based on the role of your organization, I would like to ask you if to apply for a mortgage, loans or life
insurance in Estonia, customers/former patients have to provide information about your health status and
past diseases.
And also, if to apply for mortgages and loans, a life Insurance contract is mandatory.
I hope you could help me providing more information about the regulation and the practice to access to
those financial instruments. My sincere appreciation for any sort of feedback you can provide me on the
topic. Please also, feel free to put me in contact with any other office in your Country which is in charge of
this issue.
In addition, I attach to this email a document containing the English summary of the laws passed in France,
Belgium and Luxembourg. I remain at your disposal for any additional information relating to the project.
Yours faithfully,
Grazia Scocca
Grazia Scocca
Legal Specialist
PhD, J.D.
+32 (0) 2 342 01 04
www.ecpc.org
Factsheet on the Right to be forgotten in the EU National Legislations
Legal Background and current status from France, Belgium, Luxembourg and
the Netherlands
▪ FRANCE
Legal Ref.: Articles L. 1141-5 and L. 1141-6 French Public Health Code; Law no. 2016-41,
26 January 2016 - art. 190 (V); AERAS Convention.
The provision on the right to be forgotten has been introduced in the French regulation in 2016,
as part of the Law on the modernisation of the National Health System (Law no. 2016-41, 26
January 2016).
Thanks to the reform, France endorsed the art. 190, now Article L1141-5. The rule states that
in the context of insurance or loan contracts, the period beyond which no medical information
relating to cancerous pathologies can be collected by insurer organisms may not exceed ten
years after the date of the end of the treatment or, for cancerous pathologies occurring before
age twenty-one, five years from the end of the therapeutic protocol.
Indeed, in September 2020, French authorities adopted this extension for cancer patients, from
eighteen years old to twenty-one.
The terms and deadlines are updated regularly based on therapeutic progress and scientific
data.
The content of the provision needs to be integrated by the standards in the AERAS Convention
and the other norms in the French Public Health Code (as L. 1141-2).
The AERAS Convention (S'Assurer et Emprunter avec un Risque Aggravé de Santé/Insuring
and Loaning with Aggravated Health Risk) represents a national protocol concluded between
the State, the professional organizations representing the credit institutions, the finance
companies, insurance companies, social security funding bodies and provident institutions as
well as national organizations representing patients and users of the health system or
representing disabled people. The Convention aims to facilitate access to insurance and loaning
for people presenting an aggravated risk due to their state of health or a handicap with. It
ensures that credit institutions and finance companies take full account of guarantees
alternative to insurance, defining also specific procedures for informing applicants,
investigating their files and mediating.
The Convention applies, under certain conditions, to consumers, real estate and professional
loan insurance. It fixes for mortgage loans (estate and professionals), the maximum amount to
320,000 euros and any condition of the loan duration is removed when the borrower is not more
than 70 years old at the end of the loan. For consumer loans, the maximum amount of the loan
granted without a health questionnaire is 17,000 euro.
1
A "reference table" incorporated into the AERAS (Obtaining Insurance and Credit with an
Increased Health Risk agreement) defines, for each pathology, the period after which former
patients can take out an insurance policy without any cover exclusions or having to pay an extra
premium, under the same conditions as people who have not suffered from one of these
illnesses. According to the law, the terms and time frames are regularly updated in line with
advances in treatment and scientific data.
A monitoring committee ensures the proper application of the provisions of this Convention
and respect for the commitments of the parties. Alongside this organism, it has been established
also a Committee for studies and researches, responsible for collecting and studying the
available data on mortality and morbidity caused by the main pathologies. A mediation
committee is in charge of the examination of the individual complaints by loan applicants.
At the beginning of 2017, France adopted a new decree (Decree 2017-147 of 7 February 2017)
to implement the obligation of information for insurers. By law, the insurer is responsible for
giving an “information document on the right to be forgotten” to applicants for credit
repayment insurance, at the same time as the normal risk declaration form.
The regulation has been implemented by the Decree no. 2017-173 of 13 February 2017, that
relates to the penalties applicable to any insurers that do not conform to the legal time limit for
the collection of medical information.
Since July 2019, kidney cancer, leukaemia, prostate cancer, cystic fibrosis and hepatitis C are
among the new types of pathologies included in the referred table of the AERAS Convention.
These measures have been pursued in 2020.
▪ BELGIUM
Legal Ref. : Law no. C − 2019/40839, 4 April 2019.
Promulgated in April 2019 and entered in force in February 2020, the Law modified the
Insurance regulation (Loi relative aux assurance, C − 2014/11239, 4 Avril 2014) and reformed
the article 61.
The provisions are applicable to insurance contracts concerning mortgage and professional
loans.
The new provisions in article 61/1 and 61/2 introduced the interdiction for insurance companies
to take into account previous cancer pathologies after 10 years from the end of the successful
treatment and the absence of relapse within the same period. It is considered a successful
treatment the period from the end of the active treatment and the absence of a new manifestation
of the pathology.
In May 2019, according to the provisions in article 61/3, the regulation has been implemented
through the adoption of a reference table (Doc. No. C − 2019/12990). It determined a reduced
time limit to access to the right to be forgotten for specific cancer pathologies.
2
Every two years, the Belgian Health Care Knowledge Centre (KCE) assesses the reference
table based on the medical progress and the available scientific data relating to the pathologies
referred. The Belgian monitoring office of pricing (Bureau du suivi de la tarification) is in
charge of the disputes relating to the application of the concerned provisions.
The Belgian regulation does not provide a limitation related to the amount covered by loans or
insurance contracts.
▪ LUXEMBOURG
Legal Ref.: Convention « Droit à l’oubli » - S’assurer et emprunter avec un risque de santé
aggravé en raison d’une pathologie cancéreuse ou d’une infection virale à l’hépatite C ou
d’une infection par le VIH
Since the 1st January 2020, Luxembourg has introduced the “right to be forgotten” to facilitate
insurance access for cancer survivors.
The initiative has been formalized through a Convention between Luxembourg’s Ministry of
Health, the Luxembourg Insurance and Reinsurance Association (ACA) and eight insurance
companies.
The Convention applies only and exclusively to the balance outstanding insurance for a loan
or estate loans for the acquisition of the main residence or professional facilities and whose
maximum amount does not exceed 1,000,000 euros.
It does not apply to the acquisition of a second home or rental investments.
For the same person concerned, it applies only within the limit of the maximum amount of
1,000,000 euros of cover.
According to the provisions of this Convention, the applicant cured of cancer is entitled not to
declare his pathology when the therapeutic protocol relating to this cancerous pathology has
ended for 10 years (end of active treatment of cancer by surgery, radiotherapy, chemotherapy);
or the therapeutic protocol relating to this cancerous pathology has ended for 5 years, for cancer
diagnosed before the age of 18.
During the mentioned timeframe, the absence of relapse is needed.
Apart from this specific condition, the right to be forgotten is supplemented by some
exceptions, related to the Right to be forgotten with the obligation to declare, without additional
premium.
When applying for balance outstanding insurance for a mortgage loan, the applicant cured of
specific cancers (10 specific types of cancer) or viral hepatitis C, must declare his pathology,
but if certain conditions are met, the insurer cannot exclude the insurance candidate or request
a premium.
The Convention provides the establishment of a monitoring committee, made by experts, to
ensure its proper application of the provisions and the respect of the commitments of the parties.
For this, it has the competence to examine the individual complaints addressed to it by the
applicants.
3
▪ THE NETHERLANDS
Press release from the Minister of Finance: Ex-cancer patients can better insure themselves
(10 July 2020)
The Netherlands announced an ongoing legislative process on the Right to be forgotten.
On July 10th,2020, Minister Hoekstra announced that the Council of Ministers approved
the ‘clean-slate policy’ conducing to the implementation of the Right to be forgotten by
January 2021 at the latest. According to what has been communicated the provision will
apply to death insurance policy (ORV) and funeral insurance policy.
To qualify for the clean-slate policy, a cancer survivor has to be in complete remission from
cancer for 10 years. This period is reduced to five years for those who were younger than
21 when they were diagnosed with the disease. The policy is based on the model that has
been in force in France.
As for this latter, the provision will be complemented with a list of exceptions to identify
the cancers that qualify for a period of less than 10 years. This table will include the most
common cancers affecting the 18 to 39 age group such as ovarian, testicle, skin, and breast
cancers, and certain types of blood cancer.
4
Annex
Reference Table (updated June 2020)*
*The document contains the common cancer pathologies included into the three regulations
with shorter delays than 10 years
Type of Pathology Histological types and Access time from the end
stages - of active treatment of
pre-therapeutic stages cancer pathology and
without relapse
TESTICULAR CANCER Pure seminoma, stage I 3 years
Pure seminoma, stage II 6 years
Non-seminomatous tumours
or mixed, stage I and II 6 years
BREAST CANCERS Ductal Carcinoma in situ
(IN SITU) 1 year
Locular Carcinoma in situ
MELANOMA OF SKIN Melanoma in situ or Level
Clark I
Complete exeresis 1 year
Absence of dysplastic nevus
syndrome
CERVICAL CANCER CIN III (or HSIL) or in situ 1 year
KIDNEY CANCER Renal cell carcinoma (RCC) 8 years
of clear cell morphology,
diagnosed after the age of 50
years, T1N0M0 level of the
Fuhrman grade classification
I and II
5
Chromophobe renal cell 5 years
carcinoma, T1N0M0 level
COLON AND RECTAL CANCER Stage Tis (stage 0):
- Diagnosed after the age of 1 years
50 years old
Stage I: T1N0M0:
- diagnosed after the age of
50 years 2 years
- histologic type:
adenocarcinoma
Stage I: T2N0M0:
- Diagnosed after the age of 8 years
50 years
- Histologic type:
adenocarcinoma
THYROID CANCER Papillary/Vesicular <45 year
at the diagnosis, stage I 3 years
Papillary/ vesicular 45 or 3 years
older at diagnosis, stage I or
II
6 years
Papillary/vesicular, stage III
HODGKIN'S LYMPHOMA Hodgkin’s lymphoma stage 6 years / 8 years (for
1A after a post-treatment Luxembourg)
follow-up
Hodgkin’s lymphoma stage
1B and 2A after post- 8 years / 10 years (for
treatment follow-up Luxembourg)
ACUTE PROMYELOCYTIC Regardless of the number of
LEUKAEMIA/ LAP/ LAM3 leukocytes at diagnosis 3 years / 5 (for
Luxembourg)
Treatment performed
6